Dentsply Sirona (XRAY)
(Delayed Data from NSDQ)
$25.00 USD
-1.12 (-4.29%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $25.01 +0.01 (0.04%) 7:56 PM ET
4-Sell of 5 4
A Value B Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$25.00 USD
-1.12 (-4.29%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $25.01 +0.01 (0.04%) 7:56 PM ET
4-Sell of 5 4
A Value B Growth C Momentum B VGM
Zacks News
DENTSPLY (XRAY) Earnings and Revenues Beat Estimates in Q3
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) reported third-quarter 2017 adjusted earnings per share (EPS) of 70 cents, beating the Zacks Consensus Estimate by 4 cents.
DENTSPLY (XRAY) Q3 Earnings Beat Estimates, Sales Rise Y/Y
by Zacks Equity Research
DENTSPLY reported adjusted earnings of 70 cents per share, which came above the Zacks Consensus Estimate by 4 cents and was higher than earnings of 66 cents in the year-ago quarter.
Can DENTSPLY (XRAY) Deliver a Beat This Earnings Season?
by Zacks Equity Research
In the third quarter, DENTSPLY (XRAY) is expected to witness strong growth in revenues, particularly in the dental consumables and laboratories segment.
DENTSPLY SIRONA Strong on Deal Renewals, Forex Woes Stay
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) renewed distribution deal will aid the company to gain market traction. However, forex woes remain a concern.
Top MedTech Stocks Safe from Graham-Cassidy Repeal Bill
by Zacks Equity Research
The investment climate for medical device majors has become increasingly volatile due to political potshots in Capitol Hill, for and against Obamacare.
New Strong Sell Stocks for September 12th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
New Strong Sell Stocks for August 16th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
DENTSPLY (XRAY) Earnings and Revenues Miss Estimates in Q2
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) reported lukewarm second-quarter results owing to inventory reduction related to a change in the distribution strategy in North America and lower equipment sales to end users.
DENTSPLY (XRAY) Q2 Earnings Miss Estimates, Sales Fall Y/Y
by Zacks Equity Research
DENTSPLY reported adjusted earnings of 65 cents per share, which missed the Zacks Consensus Estimate by a penny and was lower than earnings of 76 cents in the year-ago quarter.
4 Medical Product Stocks Likely to Top Q2 Earnings Estimates
by Zacks Equity Research
There are some powerful long-term tailwinds in the medical space.
Why DENTSPLY (XRAY) Might Surprise This Earnings Season
by Zacks Equity Research
DENTSPLY (XRAY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Can DENTSPLY Sirona (XRAY) Deliver a Beat in Q2 Earnings?
by Zacks Equity Research
DENTSPLY Sirona's (XRAY) results are likely to be boosted by surging dental & healthcare consumables space in the yet-to-be-reported second quarter.
Will Flowserve (FLS) Pull Off a Surprise in Q2 Earnings?
by Zacks Equity Research
We expect second-quarter results of Flowserve (FLS) to gain traction from its strong operation model, solid productivity and geographical diversity.
Why an Earnings Beat is Likely for Waters Corp. (WAT) in Q2
by Zacks Equity Research
Waters Corp.'s (WAT) dominant position in the biopharma end markets and thriving sales in emerging markets will likely help it gain traction in the second quarter.
DENTSPLY SIRONA Strong on Deal Renewals, Forex Woes Stay
by Zacks Equity Research
On Jul 12, we issued an updated research report on NY-based DENTSPLY SIRONA Inc. (XRAY) -- a global leader in the design, development, manufacture and marketing of dental consumables and dental laboratory products.
DENTSPLY SIRONA Renews Canadian Distribution Agreement
by Zacks Equity Research
DENTSPLY SIRONA Inc. (XRAY), a dental solutions company, recently announced the renewal of an existing distribution agreement with Henry Schein Canada, Inc.
DENTSPLY (XRAY) Renews Partnership with Pacific Dental
by Zacks Equity Research
DENTSPLY SIRONA Inc. (XRAY), a dental solutions company, recently announced that it has renewed its strategic partnership with Pacific Dental Services, LLC.
DENTSPLY (XRAY) Earnings and Revenues Miss Estimates in Q1
by Zacks Equity Research
DENTSPLY SIRONA Inc. (XRAY) reported adjusted earnings per share of 49 cents in the first quarter of 2017, missing the Zacks Consensus Estimate by 2 cents.
DENTSPLY (XRAY) Q1 Earnings Miss Estimates, Sales Up Y/Y
by Zacks Equity Research
DENTSPLY reported adjusted earnings of 49 cents per share, which missed the Zacks Consensus Estimate by 2 cents.
Medical Product Q1 Earnings Due on May 9: XRAY, HSIC & More
by Zacks Equity Research
Medical product, an important part of the medical device subcategory within the broader Medical sector, looks promising at the moment.
Bull of the Day: Align Technology (ALGN)
by Kevin Cook
Clearly, investors will continue to smile with this 25% grower in their portfolios
Can DENTSPLY (XRAY) Pull a Surprise this Earnings Season?
by Zacks Equity Research
DENTSPLY Sirona Inc. (XRAY), a dental solutions company, is expected to report first-quarter 2017 results on May 5.
DENTSPLY Sirona Grapples with Multiple Issues: Dump Now?
by Zacks Equity Research
On Mar 20, we issued an updated research report on NY-based DENTSPLY Sirona Inc. (XRAY) -- a global leader in the design, development, manufacture and marketing of dental consumables and dental laboratory products.
DENTSPLY (XRAY) Up 3.9% Since Earnings Report: Can It Continue?
by Zacks Equity Research
DENTSPLY (XRAY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
New Strong Sell Stocks for February 28th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today: